TS-PERIO-02
| Study Name | |
| TS–PERIO–02 | |
| ClinicalTrials.gov Identifier (if applicable) | |
| NCT05220722 | |
| Clinical Trial Category (check all that apply) | |
|
|
| Study Center | |
| Institution Name | |
| MD Anderson Cancer Center | |
| City | |
| Houston | |
| State | |
| Texas | |
| Country | |
| United States | |
| List additional Institutions (include address, phone number, and website) | |
| Rhode Island Hosptial at Brown University of Colorado Columbia University |
|
| Study Contacts | |
| Principal Investigator | |
| Dr. Milind Javle | |
| P.I. Phone | |
| (713) 792-2828 | |
| P.I. Email | |
| mjavle@mdanderson.org | |
| List additional Principal Investigators (include phone number and email) | |
| Dr. Khaldoun Almhanna, 401-606-4694, Kalmhanna@Lifespan.org Dr. Karie Runcie, kr2836@cumc.columbia.edu Dr. Sarah Davis, SARAH.DAVIS@CUANSCHUTZ.EDU |
|
| Study Coordinator | |
| Brian Witt | |
| Study Coordinator Phone | |
| (713) 563-7644 | |
| Study Coordinator Email | |
| bjwitt@mdanderson.org | |
| List additional Study Coordinators (include phone number and email) | |
| RIH: Shoira Saliev Ahunbaev, 401-444-4189, 336121@lifespan.org Colorado: McKenna Russen, (720) 848-8785, MCKENNA.RUSSEN@CUANSCHUTZ.EDU Columbia: Nadine Kuriakose, 212-304-5530, nk2947@cumc.columbia.edu |
|
| OVERVIEW – in layman’s terms (150 words max) | |
| In this study, a new delivery approach is being tested for patients with HCC and ICC. These tumors are often located in different parts of the liver. To get the drug to all tumors within your liver, this study is testing the delivery of an investigational drug called SD-101 with a TriNav device. SD-101 may stimulate the immune system. | |
| Enrollment | |
| 15-90 patients | |
| Study Start Date | |
| 05/03/2022 | |
| Estimated Completion Date | |
| 01/01/2024 | |
| Purpose of the Study – in Layman’s Terms (use the “+” to add more list items) | |
|
|
